Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice
Jamilah Abusarah, Fatemeh Khodayarian, Nehmé El-Hachem, Natasha Salame, Martin Olivier, Mohammad Balood, Katiane Roversi, Sébastien Talbot, Jean‐Pierre Bikorimana, Jingkui Chen, Mario Jolicœur, Louis‐Éric Trudeau, Samaneh Kamyabiazar, Borhane Annabi, Françis Robert, Jerry Pelletier, Abed-El-Hakim El-Kadiry, Riam Shammaa, Moutih Rafei
Abstract
production of interleukin-12, and higher chemokine secretion. This cross-presentation capacity of MSC-IPr is highly dependent on their metabolic activity. Compared with DCs, MSC-IPr hold the ability to cross-present a vastly different epitope repertoire, which translates into potent re-activation of T cell immunity against EL4 and A20 lymphomas and B16 melanoma tumors. Moreover, therapeutic vaccination of mice with pre-established tumors efficiently controls cancer growth, an effect further enhanced when combined with antibodies targeting PD-1, CTLA4, LAG3, or 4-1BB under both autologous and allogeneic settings. Therefore, MSC-IPr constitute a promising subset of non-hematopoietic antigen-presenting cells suitable for designing universal cell-based cancer vaccines.